CN107656067A - A kind of detection method and its application of assessment SLE infant total disease mobilities and kidney trouble mobility - Google Patents
A kind of detection method and its application of assessment SLE infant total disease mobilities and kidney trouble mobility Download PDFInfo
- Publication number
- CN107656067A CN107656067A CN201710839306.XA CN201710839306A CN107656067A CN 107656067 A CN107656067 A CN 107656067A CN 201710839306 A CN201710839306 A CN 201710839306A CN 107656067 A CN107656067 A CN 107656067A
- Authority
- CN
- China
- Prior art keywords
- sle
- infants
- mobility
- blood plasma
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to biomedical inspection field, and in particular to a kind of detection method and its application of assessment SLE infant total disease mobilities and kidney trouble mobility.The present invention filters out this cell factor of IP 10 in SLE infant blood plasma first, it is horizontal by detecting IP 10 in blood plasma, Disease Activity SLE infants and inactivity SLE infants can not only be distinguished well, Sensitivity and Specificity is respectively 81% and 74%, and it can be very good to distinguish kidney trouble activist and the inactive person of kidney trouble in SLE infants, sensitivity is 72.2%, specificity 60.7%.The method of the present invention improves the sensitivity and specificity of total disease activist and kidney trouble activist in diagnosis SLE infants, and simple to operate, easy to spread.
Description
Technical field
The present invention relates to field of biological medicine, specifically, be it is a kind of assess SLE infant total disease mobilities and
The detection method of kidney trouble mobility and its application.
Background technology
Systemic loupus erythematosus (SLE) is a kind of Systemic autoimmune using chronic immunity inflammation as outstanding behaviours
Disease.It can involve multiple histoorgans, and each system of whole body includes mucocutaneous, joint, urinary system, respiratory system, the heart
Vascular system or even nervous system can be involved.Although China's SLE illness rates are not high, about 70/,100,000, but total case load
Have more than 1,000,000 people, and probably 20%SLE patient falls ill in the Childhood.Compared with the SLE that is grown up, lupus in children with SLE patient
The incidence of disease of property ephritis (LN) substantially increases, and prognosis mala, is to cause one of SLE infant main causes of death.Wherein
The infant of 10% merging lupus nephritis can progress to end-stage renal disease within 5 years, and the health of children is caused very
Big harm.
Clinically Main Basiss clinical manifestation and Serological diagnose and assessed SLE disease activities, serum at present
Learning index includes complement and anti-ds-DNA antibody.Anti-ds-DNA antibody has two kinds of detection methods at present, and one kind is radioimmunology,
One kind is ELISA.Although the specificity of radioimmunology detection is higher, sensitiveness is relatively low, and complex steps, has
Radioactivity；Although ELISA sensitiveness is higher, specificity is relatively low, easily by other proteantigens such as anti-single stranded DNA
Pollution.In addition, newest research shows, with disease activity it is closely related be anti-ds-DNA antibody type rather than drop
Degree.IgG types or IgA type anti-ds-DNA antibodies, it is closely related with SLE state of an illness mobility；And IgM types anti-ds-DNA antibody then with
State of an illness activity and lupus nephritis are negatively correlated.And at present clinical detection be anti-ds-DNA antibody total titre, not yet distinguish it
Particular type, therefore it can not reflect the disease activity of SLE patient exactly.In addition, studies have reported that, there is also part
Serology activity and the lupus of clinical stability type (i.e. 6 months to 2 years without clinical state activity, but have Anti-hCG action titre
Lasting serology activity suggested by rise and/or hypocomplementemia), account for the 6%~9% of patient populations.Therefore, adopt merely
With anti-ds-DNA antibody or complement sometimes can not the accurate evaluation lupus state of an illness it is whether movable.Therefore total disease can be reflected by finding
Effective biomarker tool of mobility especially lupus nephritis mobility is of great significance, and this will be helpful to pair
The SLE infant state of an illness is monitored in real time, is carried out individualized treatment and is improved prognosis.
A series of researchs are it has been shown that the occurrence and development of SLE diseases and chronic inflammation are closely related.(1) TNF
(TNF-α) is the main proinflammatory cytokine as caused by macrophage and monocyte, has strong pro-inflammatory effect.(2) make
For a kind of important immune-regulating factor, IL-2 has various biological function.T cell exists after antigenic activation in IL-2
Under conditions of can enter the cell cycle the S phases, promote and maintain cell propagation；IL-2 can directly facilitate B cell proliferation
Differentiation and the secretion of immunoglobulin.(3) IFN-γ has extensive immunoregulation effect, can be thin with inducing macrophage and B
Cellular expression MHC II quasi-molecules, so as to improve its HLA-II antigen；Enhanced CT L cells and the energy of NK cell killing target cells
Power；Inducing cell expresses IL-2 acceptors, so as to promote T cell to breed, further expands immune response.(4) IP-10 is also known as
Gamma interferon inducible protein -10 are various cells such as T lymphocytes, NK cells, monocyte and endothelial cell by
A kind of IFN-γ cell factor secreted after stimulating.It can act on the CXCR3 acceptors on T cell surface, and assist T cell
Chemotactic is to inflammation part.(5) IL-1 β play the effect of key in auto-inflammatory reacts syndrome.IL-1 beta receptor antagonists
IL-1 β and its acceptor combination can be blocked and block downstream signaling pathway and reduce inflammatory reaction.(6) IL-17 is to send out recently
A kind of existing inflammatory cytokine.It can promote the activation of T cell and and stimulate epithelial cell, endothelial cell, into fiber finer
Born of the same parents produce cytokine profiles such as IL-6, IL-8, granulocytes-macrophages stimulating factor (GM-CSF) etc., so as to cause inflammation
Generation.In addition, platelet derived growth factor (PDGF) is a kind of important factor,mitogenic, having stimulates certain detail
The ability of born of the same parents group's division growth.PDGF has the dimeric structure of diversified forms, can be divided into PDGF-AA, PDGF-BB, PDGF-
AB, PDGF-CC and PDGF-DD.There are some researches show PDGF-BB can stimulated vascular smooth muscle cell, fibroblast and mesentery
The division and proliferation of cell.This prompting PDGF-BB may take part in mainly being showed with propagation including lupus nephritis
The occurrence and development of a variety of kidney troubles.In addition apoptosis correlation molecule Fas and FasL is also in immune tolerance and autoimmune disease
Middle performance key effect.Present invention research have detected the level of above-mentioned albumen in SLE infant blood plasma, and therefrom filter out to assessing
SLE infant total disease mobilities and kidney trouble mobility have the molecule of diagnostic value.
The content of the invention
New it is used to assess SLE infant total disease mobilities and kidney the technical problem to be solved in the present invention is to provide a kind of
The method of dirty disease activity.We are by Luminex methods to cytokine profiles in SLE infants and healthy children blood plasma
Level is detected, it is found that the level of IP-10 in SLE infant blood plasma substantially increases.In addition, disease activity SLE infant blood plasma
Middle IP-10 level is also apparently higher than inactivity SLE infants, and sensitivity and specificity routinely refer to obviously higher than laboratory
Mark such as anti-ds-DNA antibody and Complement C_3, C4.It is worth noting that, it has been found that kidney trouble activist in SLE infants
Blood plasma IP-10 level also apparently higher than the inactive person of kidney trouble in SLE infants, and in SLE infant blood plasma IP-10 water
Obvious positive correlation be present between its gentle kidney trouble activity index.Therefore IP-10 is horizontal in blood plasma, can not only be effectively
Distinguish Disease Activity SLE infants and specific can distinguish kidney trouble activist in SLE infants, and it is simple to operate, easily
In popularization.
The present invention first purpose be to be directed to deficiency of the prior art, there is provided interferon-γ inducible protein 10 or its
The purposes of detection reagent.
Second object of the present invention is to be directed to deficiency of the prior art, there is provided one kind is used to assess SLE infants totality
The method of disease activity or kidney trouble mobility.
Third object of the present invention is to be directed to deficiency of the prior art, there is provided one kind is used to assess SLE infants totality
The kit of disease activity or kidney trouble mobility.
To realize above-mentioned first purpose, the present invention adopts the technical scheme that：
In a first aspect, interferon-γ inducible protein 10 is as assessment SLE disease total disease mobilities or kidney trouble
Application in the mark of mobility.
Second aspect, application of the interferon-γ inducible protein 10 in detection reagent or detection kit is prepared are described
Detection reagent or detection kit are used for：
(a) it is used to assess whether individual suffers from SLE diseases；Or
(b) it is used to assess individual SLE total diseases mobility；Or
(c) it is used to assess individual SLE kidney troubles mobility.
The third aspect, the reagent for detecting the expression quantity of interferon-γ inducible protein 10 in individual blood plasma are preparing detection
Application in reagent or detection kit, the detection reagent or detection kit are used to assess the activity of SLE diseases total disease
Degree or kidney trouble mobility.
As the preferred embodiment of the present invention, the individual of the assessment is SLE infants.
As the preferred embodiment of the present invention, the table of interferon-γ inducible protein 10 in the individual blood plasma of detection
Reagent up to amount is the specific antibody of interferon-γ inducible protein 10.
As the preferred embodiment of the present invention, the assessment is specially：Distinguish healthy children, inactivity SLE
Infant, activity SLE infants, kidney inactivity SLE infants and kidney activity SLE infants.
To realize above-mentioned second purpose, the present invention adopts the technical scheme that：
A kind of method for assessing SLE infant total disease mobilities or kidney trouble mobility, SLE is detected first and is suffered from
IP-10 expression quantity in youngster's blood plasma, assess SLE disease total disease mobilities secondly by IP-10 expression quantity or kidney trouble is lived
Dynamic degree.
As the preferred embodiment of the present invention, the detection IP-10 expression quantity, can prepare in conventional manner
Anti- IP-10 antibody, establish detection IP-10 qualitative or quantitative method and supporting reagent or kit, the conventional method
The antibody prepared by the use of the IP-10 of heterogenous expression or the IP-10 of chemical synthesis as antigen-immunized animal experiment can be referred to.It is described
Assessed by IP-10 expression quantity, can be by IP-10 expression quantity in individual blood plasma to be detected and master sample IP-10 expression quantity
As a comparison, the master sample includes：Healthy children, inactivity SLE infants, activity SLE infants, kidney inactivity
SLE infants and kidney activity SLE infants.By comparing, SLE infant total disease mobilities and kidney trouble activity are assessed
Degree.
To realize above-mentioned 3rd purpose, the present invention adopts the technical scheme that：
A kind of kit for being used to assess SLE infant total disease mobilities or kidney trouble mobility, the kit
Include the reagent for detecting the expression quantity of interferon-γ inducible protein 10 in individual blood plasma.
As the preferred embodiment of the present invention, the table of interferon-γ inducible protein 10 in the individual blood plasma of detection
Reagent up to amount is the specific antibody of interferon-γ inducible protein 10.
Specifically, the present invention adopts the following technical scheme that：After the same day collects the peripheral blood of healthy children and SLE infants, stand
That is centrifugal separation plasma, -80 DEG C of refrigerators are stored in.To detect the IP-10 in blood plasma after all sample plasma collections are good.
1. the specification provided according to manufacturer, prepare standard items and cleaning solution.
2. the magnetic bead for mixing and being combined with various antibody is vibrated, each hole 50ul mixing magnetic beads in 96 orifice plates.
3. adding 50ul standard items per hole or sample blood plasma, room temperature lucifuge being incubated 2 hours on horizontal oscillator tube, shaking speed is
800±50rpm。
4. 96 orifice plates are fixed on magnetic board, and 2min is stood, and magnetic bead is resuspended with cleaning solution.
After 5.1min, liquid is abandoned, and patted dry on blotting paper.
6. adding 100ul cleaning solutions per hole, 1min is stood.Liquid is abandoned, and is blotted.It is repeated 3 times.
7. the detection antibody for the biotin labeling that 50ul is mixed is added per hole.
8. room temperature lucifuge is incubated 1 hour on horizontal oscillator tube, it is 800 ± 50rpm to shake speed.
9. 96 orifice plates are fixed on magnetic board, and stand 2min.Liquid is abandoned, and is patted dry on blotting paper.
10. adding 100ul cleaning solutions per hole, 1min is stood.Liquid is abandoned, and is patted dry on blotting paper.It is repeated 3 times.
11. the 50ul Streptavidin-Conjugated-PE mixed are added per hole.Room temperature lucifuge is in horizontal oscillator tube
Upper incubation 30min, it is 800 ± 50rpm to shake speed.
12. 96 orifice plates are fixed on magnetic board, and stand 2min.Liquid is abandoned, and is patted dry on blotting paper.
13. adding 100ul cleaning solutions per hole, 1min is stood.Liquid is abandoned, and is blotted.It is repeated 3 times.
14. adding 100ul cleaning solutions per hole, room temperature lucifuge oscillation incubation 2min, it is 800 ± 50rpm to shake speed.
15. detecting each magnetic bead fluorescence intensity in Luminex machines, each sample values are obtained according to standard curve.
Its content in blood plasma is detected by IP-10 ELISA kit, with assess SLE infant total disease mobilities and
Kidney trouble mobility.
The clinical sample of the present invention comes from SLE infants and healthy children peripheral blood, centrifugal separation plasma.By testing table
Bright, blood plasma IP-10 levels can not only distinguish Disease Activity SLE infants and inactivity SLE infants, sensitiveness and spy well
The opposite sex is respectively 81% and 74%, and it is non-live to can be very good to distinguish kidney trouble activist and kidney trouble in SLE infants
Dynamic person, sensitivity 72.2%, specificity 60.7%.
IP-10 is horizontal in blood plasma by detecting by the present invention, improves total disease activist and kidney in diagnosis SLE infants
The sensitivity and specificity of disease activity person, and it is simple to operate, it is easy to spread.
The present invention filters out this cell factor of IP-10 in SLE infant blood plasma first, can reflect that its total disease is lived
Dynamic degree and kidney trouble mobility, and all more conventional lab index of Sensitivity and Specificity increases.
Brief description of the drawings
Accompanying drawing 1 is 9 kinds of cytokine levels schematic diagrames in healthy children in the embodiment of the present invention 1 and SLE infant blood plasma.
Accompanying drawing 2, which is that IP-10 is horizontal in blood plasma, distinguishes SLE infant total disease mobility schematic diagrames.Wherein 2A is healthy youngster
IP-10 level in virgin, inactivity SLE infants and activity SLE infant blood plasma；2B is that IP-10 distinguishes SLE infants in blood plasma
The ROC curve of total disease mobility.
Accompanying drawing 3, which is that IP-10 is horizontal in blood plasma, distinguishes SLE infant kidney trouble mobility schematic diagrames.Wherein 3A is healthy youngster
IP-10 level in virgin, kidney inactivity SLE infants and kidney activity SLE infant blood plasma；3B is IP-10 areas in blood plasma
Divide the ROC curve of SLE infant kidney trouble mobilities.
Accompanying drawing 4 is the horizontal schematic diagrames with kidney trouble mobility correlation analysis of SLE infant blood plasma IP-10.
Embodiment
The invention will be further elucidated with reference to specific embodiments.It should be understood that these embodiments are merely to illustrate this hair
Bright rather than limitation the scope of the present invention.In addition, it is to be understood that after the content of the invention recorded has been read, art technology
Personnel can make various changes or modifications to the present invention, and these equivalent form of values equally fall within the application appended claims and limited
Fixed scope.
Embodiment 1：
First, experimental method
Luminex multiple cytokines (TNF-α, PDGF-BB, IP-10, IL-1 β, IFN-γ, IL-17A, IL-2, Fas,
FasL) detect
Reagent is the Magnetic Luminex Screening Assay Human Premixed Multi- of R＆D companies
Analyte Kit (article No. LXSAHM-12).
1. the specification provided according to manufacturer, prepare standard items and cleaning solution.
2. the magnetic bead for mixing and being combined with various antibody is vibrated, each hole 50ul mixing magnetic beads in 96 orifice plates.
3. adding 50ul standard items per hole or sample blood plasma, room temperature lucifuge being incubated 2 hours on horizontal oscillator tube, shaking speed is
800±50rpm。
4. 96 orifice plates are fixed on magnetic board, and 2min is stood, and magnetic bead is resuspended with cleaning solution.
After 5.1min, liquid is abandoned, and patted dry on blotting paper.
6. adding 100ul cleaning solutions per hole, 1min is stood.Liquid is abandoned, and is blotted.It is repeated 3 times.
7. the detection antibody for the biotin labeling that 50ul is mixed is added per hole.
8. room temperature lucifuge is incubated 1 hour on horizontal oscillator tube, it is 800 ± 50rpm to shake speed.
9. 96 orifice plates are fixed on magnetic board, and stand 2min.Liquid is abandoned, and is patted dry on blotting paper.
10. adding 100ul cleaning solutions per hole, 1min is stood.Liquid is abandoned, and is patted dry on blotting paper.It is repeated 3 times.
11. the 50ul Streptavidin-Conjugated-PE mixed are added per hole.Room temperature lucifuge is in horizontal oscillator tube
Upper incubation 30min, it is 800 ± 50rpm to shake speed.
12. 96 orifice plates are fixed on magnetic board, and stand 2min.Liquid is abandoned, and is patted dry on blotting paper.
13. adding 100ul cleaning solutions per hole, 1min is stood.Liquid is abandoned, and is blotted.It is repeated 3 times.
14. adding 100ul cleaning solutions per hole, room temperature lucifuge oscillation incubation 2min, it is 800 ± 50rpm to shake speed.
15. detecting each magnetic bead fluorescence intensity in Luminex machines, each sample values are obtained according to standard curve.
2nd, testing result
Fig. 1 is 9 kinds of cytokine levels schematic diagrames in healthy children in the embodiment of the present invention 1 and SLE infant blood plasma.
Fig. 2, which is that IP-10 is horizontal in blood plasma, distinguishes SLE infant total disease mobility schematic diagrames.Wherein 2A be healthy children,
IP-10 level in inactivity SLE infants and activity SLE infant blood plasma；2B is that IP-10 differentiations SLE infants are total in blood plasma
The ROC curve of body disease activity.
Fig. 3, which is that IP-10 is horizontal in blood plasma, distinguishes SLE infant kidney trouble mobility schematic diagrames.Wherein 3A be healthy children,
IP-10 level in kidney inactivity SLE infants and kidney activity SLE infant blood plasma；3B is that IP-10 is distinguished in blood plasma
The ROC curve of SLE infant kidney trouble mobilities.
Fig. 4 is the horizontal schematic diagrames with kidney trouble mobility correlation analysis of SLE infant blood plasma IP-10.
Table 1 is laboratory conventional detection index anti-double-chain DNA and Complement C_3, C4 and blood plasma IP-10 in differentiation SLE totality
Sensitivity and specific analytical table in terms of disease activity.
Table 1
The level of cytokine profiles in SLE infants and healthy children blood plasma is detected by Luminex methods,
It was found that IP-10 level substantially increases in SLE infant blood plasma.In addition, in disease activity SLE infant blood plasma IP-10 it is horizontal
Apparently higher than inactivity SLE infants, and sensitivity and specificity resist obviously higher than laboratory conventional index such as Anti-ds-DNA antibodies
Body and Complement C_3, C4 etc..It is worth noting that, it has been found that the blood plasma IP-10 of kidney trouble activist water in SLE infants
It is flat also apparently higher than the inactive person of kidney trouble in SLE infants, and in SLE infant blood plasma IP-10 level and its kidney trouble
Obvious positive correlation between activity index be present.Therefore IP-10 is horizontal in detection patients blood plasma, can not only efficiently differentiate disease
Sick activity SLE infants, and specific kidney trouble activist in SLE infants can be distinguished, and it is simple to operate, it is easy to push away
Extensively.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of the inventive method is not departed from, can also make some improvement and supplement, and these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (9)
1. interferon-γ inducible protein 10 is as the mark for assessing SLE disease total disease mobilities or kidney trouble mobility
Application in will thing.
2. application of the interferon-γ inducible protein 10 in detection reagent or detection kit is prepared, it is characterised in that described
Detection reagent or detection kit are used for：
(a) it is used to assess whether individual suffers from SLE diseases；Or
(b) it is used to assess individual SLE total diseases mobility；Or
(c) it is used to assess individual SLE kidney troubles mobility.
3. preparing detection reagent or detection examination for the reagent for detecting the expression quantity of interferon-γ inducible protein 10 in individual blood plasma
Application in agent box, it is characterised in that the detection reagent or detection kit are used to assess SLE disease total disease mobilities
Or kidney trouble mobility.
4. according to the application described in claim 1-3, it is characterised in that the individual of the assessment is SLE infants.
5. application according to claim 3, it is characterised in that interferon-γ inducible protein in the individual blood plasma of detection
The reagent of 10 expression quantity is the specific antibody of interferon-γ inducible protein 10.
6. according to the application described in claim 1-3, it is characterised in that the assessment is specially：Distinguish healthy children, inactive
Property SLE infants, activity SLE infants, kidney inactivity SLE infants and kidney activity SLE infants.
A kind of 7. method for assessing SLE infant total disease mobilities or kidney trouble mobility, it is characterised in that detection
IP-10 expression quantity in SLE infant blood plasma, SLE disease total disease mobilities are assessed by IP-10 expression quantity or kidney trouble is lived
Dynamic degree.
A kind of 8. kit for being used to assess SLE infant total disease mobilities or kidney trouble mobility, it is characterised in that institute
State kit and include the reagent for detecting the expression quantity of interferon-γ inducible protein 10 in individual blood plasma.
9. kit according to claim 8, it is characterised in that interferon-γ induction egg in the individual blood plasma of detection
The reagent of white 10 expression quantity is the specific antibody of interferon-γ inducible protein 10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710839306.XA CN107656067B (en) | 2017-09-18 | 2017-09-18 | A kind of detection method and its application for assessing SLE infant total disease mobility and kidney trouble mobility |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710839306.XA CN107656067B (en) | 2017-09-18 | 2017-09-18 | A kind of detection method and its application for assessing SLE infant total disease mobility and kidney trouble mobility |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107656067A true CN107656067A (en) | 2018-02-02 |
| CN107656067B CN107656067B (en) | 2019-11-15 |
Family
ID=61130263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710839306.XA Expired - Fee Related CN107656067B (en) | 2017-09-18 | 2017-09-18 | A kind of detection method and its application for assessing SLE infant total disease mobility and kidney trouble mobility |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107656067B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110412290A (en) * | 2019-07-29 | 2019-11-05 | 冯仕品 | SLE total disease mobility and kidney trouble mobility information detecting system |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003047331A2 (en) * | 2001-12-04 | 2003-06-12 | Nereus Pharmaceuticals,Inc. | Methods and apparatus for cell based screening |
| WO2005002416A2 (en) * | 2003-06-04 | 2005-01-13 | Joslin Diabetes Center, Inc. | Predictors of renal disease |
| CN1889979A (en) * | 2003-12-10 | 2007-01-03 | 米德列斯公司 | IP-10 antibodies and their uses |
| WO2014003744A1 (en) * | 2012-06-27 | 2014-01-03 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl 10, anti-cxcl 11, anti-cxcl 13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder |
| WO2017140794A1 (en) * | 2016-02-16 | 2017-08-24 | Celltrend Gmbh | Anti-cxc chemokine receptor antibodies and c-x-c chemokines for the diagnosis of autoimmune disease and graft-versus-host disease |
-
2017
- 2017-09-18 CN CN201710839306.XA patent/CN107656067B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003047331A2 (en) * | 2001-12-04 | 2003-06-12 | Nereus Pharmaceuticals,Inc. | Methods and apparatus for cell based screening |
| WO2005002416A2 (en) * | 2003-06-04 | 2005-01-13 | Joslin Diabetes Center, Inc. | Predictors of renal disease |
| CN1889979A (en) * | 2003-12-10 | 2007-01-03 | 米德列斯公司 | IP-10 antibodies and their uses |
| WO2014003744A1 (en) * | 2012-06-27 | 2014-01-03 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl 10, anti-cxcl 11, anti-cxcl 13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder |
| WO2017140794A1 (en) * | 2016-02-16 | 2017-08-24 | Celltrend Gmbh | Anti-cxc chemokine receptor antibodies and c-x-c chemokines for the diagnosis of autoimmune disease and graft-versus-host disease |
Non-Patent Citations (10)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110412290A (en) * | 2019-07-29 | 2019-11-05 | 冯仕品 | SLE total disease mobility and kidney trouble mobility information detecting system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107656067B (en) | 2019-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101352222B1 (en) | Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products | |
| Burska et al. | Cytokines as biomarkers in rheumatoid arthritis | |
| Venugopalan et al. | Cytokines in acute chikungunya | |
| Hyams et al. | Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease | |
| Landi et al. | Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome | |
| González-Serrano et al. | Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with X-linked agammaglobulinemia | |
| Peng et al. | Increased number of Th22 cells and correlation with Th17 cells in peripheral blood of patients with IgA nephropathy | |
| Chen et al. | Expression of T-helper-associated cytokines in patients with type 2 diabetes mellitus with retinopathy | |
| Maczynska et al. | Proinflammatory cytokine (IL-1β, IL-6, IL-12, IL-18 and TNF-α) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE) | |
| Korpinen et al. | Urinary transforming growth factor-beta1 and alpha1-microglobulin in children and adolescents with type 1 diabetes. | |
| JP2011158486A (en) | Pyrogenicity test for use with automated immunoassay systems | |
| Ishikawa et al. | Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis | |
| Papadopoulos et al. | Assessment of interleukins IL-4, IL-6, IL-8, IL-10 in acute urticaria | |
| WO2013184660A1 (en) | Methods for diagnosing osteoarthritis | |
| YATES et al. | Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis—total and specific IgE levels | |
| Aref et al. | Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia | |
| CN103487572B (en) | Application of the folliculus helper T cell (Tfh) in autoimmune disease state of an illness early warning | |
| Chong et al. | Serum fractalkine (CX3CL1) concentration correlates with clinical severity in pediatric atopic dermatitis patients | |
| Lee et al. | The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease | |
| Ponchel et al. | P037 Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis? | |
| Rajaei et al. | Evaluating the relationship between serum level of interleukin-6 and rheumatoid arthritis severity and disease activity | |
| Vijatov-Djuric et al. | Interleukin-17A levels increase in serum of children with juvenile idiopathic arthritis | |
| CN107656067B (en) | A kind of detection method and its application for assessing SLE infant total disease mobility and kidney trouble mobility | |
| Antonelli et al. | High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia | |
| Jyonouchi et al. | Age-dependent changes in peripheral blood dendritic cell subsets in normal children and children with specific polysaccharide antibody deficiency (SPAD) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191115 Termination date: 20200918 |